Latest Breaking News On - நிறுவனம் க்கு தரம் - Page 1 : comparemela.com

IQWiG finds no benefit of high-flow therapy for COPD and type 1 respiratory failure No benefit of high-flow therapy (HFT) can be derived from the available study data for patients with advanced chronic obstructive pulmonary disease (COPD) or chronic type 1 respiratory failure. It therefore remains unclear whether this form of treatment has advantages over long-term oxygen therapy (LTOT) or non-invasive ventilation (NIV). This is the conclusion of the benefit assessment that the Institute for Quality and Efficiency in Health Care (IQWiG) has now completed. The Federal Joint Committee (G-BA) had commissioned IQWiG to investigate the advantages and disadvantages of HFT in patients with stable, advanced COPD or chronic respiratory failure with oxygen deficiency (chronic type 1 respiratory failure). Treatment was to be self-administered at home, in inpatient care or rehab, etc.

Emily hendersonEfficiency in health care iqwiInstitute for qualityHealth careFederal joint committeeஎமிலி ஹென்டர்சன்நிறுவனம் க்கு தரம்ஆரோக்கியம் பராமரிப்புகூட்டாட்சியின் கூட்டு குழு